TrialClinics (Sao Paulo, Brazil)2016

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.

Roberto Hegg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.